NewAmsterdam Pharma Company N.V. Stock Nasdaq
Stocks
NAMS
NL00150012L7
Biotechnology & Medical Research
|
Market Closed -
Nasdaq
16:00:00 2026-09-18 EDT
|
5-day change | 1st Jan Change | ||
| 22.49 USD | +2.55% |
|
-1.36% | -35.89% |
| 08-26 | NewAmsterdam Pharma Presents Data From Obicetrapib Development Program At European Society Of Cardiology Congress 2026 | CI |
| 08-14 | Newamsterdam Pharma Company N.V. Announces Executive Changes | CI |
| Market Cap | 2.34B 2.69B 2.21B 2.01B 3.77B 258B 3.78B 26.51B 10.23B 131B 10.1B 9.87B 422B | P/E 2026 * |
-11.9x | P/E 2027 * | -12.8x |
|---|---|---|---|---|---|
| Enterprise Value | 1.92B 2.2B 1.81B 1.65B 3.09B 211B 3.1B 21.72B 8.38B 107B 8.27B 8.09B 346B | EV / Sales 2026 * |
78.1x | EV / Sales 2027 * | 14.7x |
| Free-Float |
99.1% | Yield 2026 * |
-
| Yield 2027 * | - |
| Markets | Quality | ||
|---|---|---|---|
Nasdaq
| NAMS | End-of-day quote | |
Nasdaq
| NAMS | Delayed | |
|
CBOE
| NAMS | Real-time | |
|
Tradegate
| KH6 | Real-time | |
|
Boerse Muenchen
| KH6 | Real-time | |
|
Börse Stuttgart
| KH6 | Delayed | |
|
Deutsche Boerse AG
| KH6 | Delayed |
Last Transcript: NewAmsterdam Pharma Company N.V.
| 1 week | -1.36% | ||
| Current month | -11.25% | ||
| 1 month | -17.47% | ||
| 3 months | -24.61% | ||
| 6 months | -23.61% | ||
| Current year | -35.89% |
| 1 week | 21.02 |  | 23.11 |
| 1 month | 21.02 | | 28.76 |
| 3 years | 5.63 | | 42.2 |
| Manager | Title | Age | Since |
|---|---|---|---|
Michael Davidson
CEO | Chief Executive Officer | 69 | 2022-10-31 |
Mayur Somaiya
DFI | Director of Finance/CFO | 52 | 2023-10-22 |
John Kastelein
CTO | Chief Tech/Sci/R&D Officer | 72 | 2022-10-31 |
| Director | Title | Age | Since |
|---|---|---|---|
Michael Davidson
BRD | Director/Board Member | 69 | 2022-10-31 |
John Kastelein
BRD | Director/Board Member | 72 | 2022-10-31 |
James Topper
BRD | Director/Board Member | 64 | 2022-10-31 |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | +2.55% | -1.36% | -15.86% | +129.02% | 2.69B | |
| -0.31% | +5.79% | +47.13% | +99.00% | 70.88B | |
| +0.39% | +2.06% | +39.38% | +78.27% | 62.49B | |
| +0.50% | +7.13% | +33.27% | +16.01% | 26.34B | |
| -3.21% | -7.27% | -17.10% | +356.10% | 26.21B | |
| -2.64% | -0.69% | -0.17% | -13.01% | 24.13B | |
| +0.71% | +8.03% | +25.03% | -12.74% | 20.72B | |
| -1.26% | -7.81% | +156.15% | +320.43% | 15.36B | |
| -0.22% | +3.99% | +45.54% | +172.46% | 14.46B | |
| +0.73% | +1.71% | -5.51% | +849.47% | 14.24B | |
| Average | -0.59% | +1.65% | +30.79% | +199.50% | 30.54B | |
| Weighted average by Cap. | -0.47% | +1.44% | +34.88% | +147.54% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | 24.6M 28.21M 23.23M 21.09M 39.52M 2.71B 39.69M 278M 107M 1.38B 106M 104M 4.43B | 122M 139M 115M 104M 195M 13.38B 196M 1.38B 531M 6.8B 524M 512M 21.89B |
| Net income | -202M -232M -191M -173M -324M -22.23B -326M -2.28B -882M -11.3B -870M -851M -36.36B | -195M -224M -184M -167M -313M -21.45B -314M -2.2B -851M -10.91B -840M -821M -35.09B |
| Net Debt | -424M -486M -400M -363M -681M -46.62B -683M -4.79B -1.85B -23.7B -1.83B -1.78B -76.26B | -556M -638M -525M -477M -894M -61.22B -898M -6.29B -2.43B -31.13B -2.4B -2.34B -100B |
| Date | Price | Change |
|---|---|---|
| 26-09-18 | US$22.49 | +2.55% |
| 26-09-17 | US$21.93 | +3.54% |
| 26-09-16 | US$21.18 | +0.09% |
| 26-09-15 | US$21.16 | -5.37% |
| 26-09-14 | US$22.36 | -1.93% |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
Quarterly revenue - Rate of surprise
- Stock Market
- Stocks
- NAMS Stock
- NAMS Stock
Select your edition
All financial news and data tailored to specific country editions
